Paper Details

  1. Home
  2. Paper Details

Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues.

Author: LeungNancy

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Nucleos(t)ide analogues (NUCs), particularly entecavir and tenofovir, are the preferred treatment for chronic hepatitis B (CHB) in the immune clearance phase. They offer high efficacy and low risk of resistance development, making them the most favorable option in many patients.
Paper Details　
Original Abstract of the Article :
HBeAg seropositivity is a marker for active viral replication. In the natural history of chronic hepatitis B infection, HBeAg marks the first two of the four phases, namely the immune tolerant phase and the immune clearance phase, and is associated with highly replicative activity of the hepatitis B...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1478-3231.2010.02387.x

データ提供：米国国立医学図書館（NLM）

Treatment of HBeAg-positive Chronic Hepatitis B with Nucleos(t)ide Analogues

Chronic hepatitis B (HBV) is a persistent infection that can leave patients stranded in a desert of liver disease. HBeAg seropositivity, a marker of active viral replication, is a crucial signpost in the progression of HBV infection. This study navigates the landscape of antiviral therapies for HBeAg-positive chronic HBV, focusing on the role of nucleos(t)ide analogues (NUCs). The researchers explore the efficacy and safety of NUCs in treating patients in the immune clearance phase, a critical stage of HBV infection. They discuss the advantages and limitations of NUCs compared to interferon-based therapies, highlighting the importance of personalized treatment approaches for optimizing patient outcomes.

Nucleos(t)ide Analogues: A Oasis in the Desert of Hepatitis B

This study highlights the significant role of NUCs in managing HBeAg-positive chronic HBV. NUCs have emerged as a valuable tool for suppressing viral replication, improving liver function, and reducing the risk of complications like hepatocellular carcinoma. The findings underscore the importance of carefully considering the individual patient's needs and the specific characteristics of the virus when choosing between NUCs and interferon-based therapies.

Navigating the Landscape of Hepatitis B Treatment

For patients with chronic HBV, finding the right treatment path can be a daunting journey. This study provides valuable insights into the effectiveness and safety of NUCs, offering hope for improved outcomes in patients with HBeAg-positive chronic HBV. The researchers highlight the importance of a personalized approach, considering the patient's individual circumstances, the viral load, and other factors to optimize treatment strategies and minimize the risk of complications.

Dr.Camel's Conclusion

This study provides a comprehensive overview of the current landscape of antiviral therapies for HBeAg-positive chronic HBV. The findings underscore the importance of NUCs in managing this challenging infection, offering a beacon of hope for patients seeking to navigate the desert of chronic liver disease. Further research is crucial to understand the long-term efficacy and safety of NUCs, ultimately aiming to improve the lives of individuals affected by HBV.

Date :
  1. Date Completed 2011-05-17
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

21205143

DOI: Digital Object Identifier

10.1111/j.1478-3231.2010.02387.x

Related Literature

Article Analysis
・Side Effects of telbivudine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.